Analysis Clinical trials

Vercise DBS instruction recall: why IFU corrections matter to trial teams

Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.

VigiEye editorial · Mon 16 Nov 2026

What happened

On 13 November 2026 Health Canada listed a Type II recall in which Boston Scientific is correcting the instructions for use (IFU) for Vercise Clinician Programmers, part of the Vercise deep brain stimulation (DBS) system. The correction covers two topics: how often the implantable pulse generator (IPG) needs recharging, and the estimates given for battery longevity.

The record describes a correction to written instructions. It does not describe a hardware fault, a software defect or a device removal. It also does not say what the revised intervals or estimates are, how many units are affected, whether any patient harm was reported, or whether regulators outside Canada have taken parallel action. Those details sit in the notice and the manufacturer's communication, not in the summary.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →